MEDCL Share Price Performance
€0
-16.45 (-100.00%)
Price €0
Fair Value€35.07
Share Pricen/a
Narrative Update • Aug 04
MedinCell S.A. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
MEDCL Community Narratives
AN
Fair Value
·Fair Value €35.07 31.3% undervalued intrinsic discount
Analysts Lift MedinCell Price Target on Strong Revenue Outlook and Positive Regulatory Developments
2users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value
·Fair Value €30 19.7% undervalued intrinsic discount
Long Acting Injectables Will Face Setbacks Before Delivering The Upside I Expect
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value €39 38.2% undervalued intrinsic discount
Long Acting Injectables Will Drive Major Long Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Long Acting Injectables Will Drive Major Long Term Upside Potential
MedinCell could see a step-change as its partner-led long-acting shots for mental health move closer to wider use, turning today’s development work into recurring royalty income. The upside hinges on key launches and partners executing smoothly, while tougher competition or delays could push out the path to consistent profits.Read more
AN
€39
38.2% undervalued intrinsic discount
Fair Value
Profit Margin
96.33%
Future PE
14.95x
Price in 2029
€46
Long Acting Injectables Will Face Setbacks Before Delivering The Upside I Expect
MedinCell’s long-acting shots could ride a real shift toward treatments that last longer, but near-term bumps may come from regulators, insurers, and partner timelines. If its flagship partnered medicine keeps gaining traction and new programs move forward, the payoff could be meaningful—yet delays and rising research spend may test patience.Read more
AN
€30
19.7% undervalued intrinsic discount
Fair Value
Profit Margin
23.25%
Future PE
60.84x
Price in 2029
€36.09
Analysts Lift MedinCell Price Target on Strong Revenue Outlook and Positive Regulatory Developments
MedinCell is riding growing demand for long-acting injectable medicines as its lead treatment gains traction, and new uses could broaden who it helps. Extended patent protection and big-name partnerships could support growth, but the business still depends heavily on a small number of launches and approvals going its way.Read more
AN
€35.07
31.3% undervalued intrinsic discount
Fair Value
Profit Margin
46.34%
Future PE
35.18x
Price in 2029
€42.19
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
MEDCL: Funding And Pipeline Milestones Will Support Long-Term Upside Potential
Fair Value: €39 38.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
MEDCL: Fair Outlook Balances Regulatory Milestone Prospects With Execution And Funding Risks
Fair Value: €30 19.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
MEDCL: Long Acting Schizophrenia Injection Pipeline Will Drive Future Share Price Upside
Fair Value: €35.07 31.3% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
MedinCell S.A. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Dec 08, 2026
- -0.87
- 100.00%
- -128.88%
- 2,269.2%
About MEDCL
- Founded
- 2003
- Employees
- 141
- CEO
- WebsiteView website
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of post-operative pain and inflammation. In addition, the company engages in the development of products in preclinical stage, including mdc-WWM for contraception; mdc-STM for the treatment of malaria; and mdc-AbbVie-1. It has strategic collaborations with TEVA, AIC, ABBVIE, Unitaid, and Gates Foundation. The company was incorporated in 2003 and is headquartered in Jacou, France.
